CAR T-cell therapy uses the target specificity of antibody therapy to direct the cytotoxic immune response3

The autologous anti-CD19 CAR T-cell therapy, TECARTUS, is individually prepared from each patient’s T cells in a 6-step process2:

Leukapheresis

Leukapheresis

Obtain peripheral blood mononuclear cells

T cells

Selection

Isolate T cells to reduce the likelihood that circulating tumor cells drive the exhaustion of CAR T cells

anti-CD3 and anti-CD28 antibodies + IL-2

Activation

Activate T cells using anti-CD3 and anti-CD28 antibodies + IL-2

anti-CD19 CAR transgene

Transduction

Insert anti-CD19 CAR transgene

CAR T cell expansion

T Cell Expansion

In cell culture, expand the number of CAR T cells to achieve dose

CAR T cells in suspension for infusion

Suspension

Formulate CAR T cells into suspension for infusion

CAR=chimeric antigen receptor; IL=interleukin.

References: 1. Kite, a Gilead Company [press release]. U.S. FDA approves Kite's TECARTUS™, the first and only CAR T treatment for relapsed or refractory mantle cell lymphoma. Published July 24, 2020. https://www.businesswire.com/news/home/20200724005428/en/U.S.-FDA-Approves-Kite%E2%80%99s-Tecartus%E2%84%A2-CAR-Treatment. Accessed July 24, 2020. 2. TECARTUS™ (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2020. 3. Feins S, Kong W, Williams EF, Milone MC, and Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(suppl 1):S3-S9.